BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Affinium Pharmaceuticals 

7000 North Mopac Expwy.
2nd Floor
Austin  Texas  78731  U.S.A.
Phone: 416-645-6614 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical

Segment
Proteomics





 Company News
Debiopharm To Acquire Affinium Pharmaceuticals's Antibiotic Clinical Assets And Platform To Identify And Develop Targeted Antibiotics 2/11/2014 9:38:38 AM
Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation By The FDA For AFN-1252 And Completion Of Dosing Of AFN-1720 Phase 1 Trial 11/12/2013 11:51:21 AM
Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round 9/5/2013 9:18:55 AM
Positive Results From Affinium Pharmaceuticals' Phase 2a Clinical Trial of AFN-1252 in ABSSSI 3/21/2013 7:36:16 AM
Affinium Pharmaceuticals Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections 8/7/2012 10:36:13 AM
Affinium Pharmaceuticals Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial 5/2/2011 8:45:39 AM
Affinium Pharmaceuticals to Present at Super Bugs - Super Drugs Conference in London, UK 3/15/2011 6:44:34 AM
Affinium Pharmaceuticals Announces the Initiation of a Phase I Clinical Trial Using an Optimized Oral Formulation of AFN-1252, its Novel Anti-staphylococcal Antibiotic 4/12/2010 10:55:19 AM
GlaxoSmithKline (GSK), Novartis AG, Pfizer Inc. (PFE), AstraZeneca AB, Albert Einstein College of Medicine, Centers for Disease Control and Prevention (CDC), And AstraZeneca AB Explore Advances in Anti-Infective Drug Development 12/9/2009 10:35:53 AM
Affinium Pharmaceuticals Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 3/4/2008 8:49:13 AM
12